CKR-5 Antibody (T21/8): sc-53792
- CKR-5 Antibody (T21/8) is a mouse monoclonal mouse IgG1 κ κ, cited in 1 publications, provided at 200 µg/ml
- raised against CKR-5 of human origin
- recommended for detection of CKR-5 of mouse, rat and human origin by WB, IP, IF and FCM
- available conjugated to either phycoerythrin or FITC for IF, IHC(P) and FCM
- m-IgG Fc BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for CKR-5 Antibody (T21/8) for WB applications. These reagents are now offered in bundles with CKR-5 Antibody (T21/8) (see ordering information below).
CKR-5 Antibody (T21/8) is a mouse monoclonal IgG1 antibody that detects CKR-5 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CKR-5, a member of the C-C chemokine receptor family, plays a crucial role in the immune response by acting as a receptor for various chemokines, which are essential for the chemotaxis of immune cells to sites of inflammation. This receptor serves as a coreceptor for HIV, facilitating viral entry into host cells alongside CD4. The interaction between CKR-5 and HIV is critical for understanding the mechanisms of viral infection and pathogenesis, as CKR-5 tends to associate with macrophage-tropic strains of the virus. The ability of CKR-5 to mediate the migration of immune cells not only highlights CKR-5′s importance in immune surveillance but also underscores CKR-5′s potential as a therapeutic target in HIV research and treatment strategies. Anti-CKR-5 antibody (T21/8) serves as an invaluable tool for researchers investigating the dynamics of immune responses and the intricate relationships between chemokine signaling and viral infections.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CKR-5 Antibody (T21/8) References:
- CC chemokine receptor 5 (CCR5) mRNA expression in pulmonary sarcoidosis. | Petrek, M., et al. 2002. Immunol Lett. 80: 189-93. PMID: 11803051
- C-C chemokine receptor type 5 (CCR5) utilization of transmitted and early founder human immunodeficiency virus type 1 envelopes and sensitivity to small-molecule CCR5 inhibitors. | Hu, Q., et al. 2010. J Gen Virol. 91: 2965-73. PMID: 20810746
- CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network. | Escola, JM., et al. 2010. J Biol Chem. 285: 41772-80. PMID: 21041313
- Editing CCR5: a novel approach to HIV gene therapy. | Cornu, TI., et al. 2015. Adv Exp Med Biol. 848: 117-30. PMID: 25757618
- Molecular Mechanism of Action for Allosteric Modulators and Agonists in CC-chemokine Receptor 5 (CCR5). | Karlshøj, S., et al. 2016. J Biol Chem. 291: 26860-26874. PMID: 27834679
- The Expanding Therapeutic Perspective of CCR5 Blockade. | Vangelista, L. and Vento, S. 2017. Front Immunol. 8: 1981. PMID: 29375583
- Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme. | Kranjc, MK., et al. 2019. Radiol Oncol. 53: 397-406. PMID: 31747383
- Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. | Ellwanger, JH., et al. 2020. Virus Res. 286: 198040. PMID: 32479976
- Dual role for CXCR3 and CCR5 in asthmatic type 1 inflammation. | Gauthier, M., et al. 2022. J Allergy Clin Immunol. 149: 113-124.e7. PMID: 34146578
- A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. | Doranz, BJ., et al. 1996. Cell. 85: 1149-58. PMID: 8674120
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CKR-5 Antibody (T21/8) | sc-53792 | 200 µg/ml | $322.00 | |||
CKR-5 Antibody (T21/8): m-IgG Fc BP-HRP Bundle | sc-537001 | 200 µg Ab; 10 µg BP | $361.00 | |||
CKR-5 Antibody (T21/8): m-IgGκ BP-HRP Bundle | sc-534181 | 200 µg Ab; 40 µg BP | $361.00 | |||
CKR-5 Antibody (T21/8) FITC | sc-53792 FITC | 200 µg/ml | $336.00 | |||
CKR-5 Antibody (T21/8) PE | sc-53792 PE | 200 µg/ml | $349.00 |